Dexamethasone intravitreal implantfor the treatment of noninfectious uveitis

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 1612-1621

  Hunter, Rebecca S ^a   Lobo, Ann Marie ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Corticosteroids; Dexamethasone implant; Macular edema; Uveitis

Indexed keywords

ANTIGLAUCOMA AGENT; CORTICOSTEROID; DEXAMETHASONE; FLUOCINOLONE; FLUOCINOLONE ACETONIDE; METHYLPREDNISOLONE; NANOPARTICLE; POLYGLACTIN; POLYMER; PREDNISONE; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE;

ANTIINFLAMMATORY ACTIVITY; BIODEGRADABILITY; CATARACT; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG SOLUBILITY; EYE INFLAMMATION; GLAUCOMA; HUMAN; IMPLANT; NONHUMAN; NONINFECTIOUS UVEITIS; PHARMACODYNAMICS; RECURRENT DISEASE; RETINA MACULA EDEMA; REVIEW; SUSTAINED RELEASE PREPARATION; SYSTEMIC DISEASE; UVEITIS; VISUAL IMPAIRMENT;

EID: 81155135095     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Albert DM, Jakobiec FA, editors. Principles and Practice of Ophthalmology. 2nd ed. Philadelphia, PA: WB Saunders Co; 2000.
2. Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol. 1987;103(2):234-235.
3. Jabs DA, Akpek EK. Immunosuppression for posterior uveitis. Retina. 2005;25(1):1-18.
4. Taylor SR, Isa H, Joshi L, Lightman S. New developments in corticosteroid therapy for uveitis. Ophthalmologica. 2010;224 Suppl 1:46-53.
5. Leopold IH, Purnell JE, Cannon EJ, Steinmetz CG, McDonald PR. Local and systemic cortisone in ocular disease. Am J Ophthalmol. 1951;34(3): 361-371.
6. Yeh S, Nussenblatt RB. Fluocinolone acetonide for the treatment of uveitis: weighing the balance between local and systemic immunosuppression. Arch Ophthalmol. 2008;126(9):1287-1289.
7. Kiernan DF, Mieler WF. The use of intraocular corticosteroids. Expert Opin Pharmacother. 2009;10(15):2511-2525.
8. Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology. 2005;112(11): 1916. e1-e7.
9. van Kooij B, Rothova A, de Vries P. The pros and cons of intravitreal triamcinolone injections for uveitis and inflammatory cystoid macular edema. Ocul Immunol Inflamm. 2006;14(2):73-85.
10. Nguyen QD, Callanan D, Dugel P, Godfrey DG, Goldstein DA, Wilensky JT. Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage. Proceedings of an expert panel roundtable discussion. Retina. 2006;Suppl:1-16.
11. Lobo AM, Sobrin L, Papaliodis GN. Drug delivery options for the treatment of ocular inflammation. Semin Ophthalmol. 2010;25(5-6): 283-288.
12. Jaffe GJ, Pearson PA, Ashton P. Dexamethasone sustained drug delivery implant for the treatment of severe uveitis. Retina. 2000;20(4):402-403.
13. Jaffe GJ, Ben-Nun J, Guo H, Dunn JP, Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 2000;107(11):2024-2033.
14. Brumm MV, Nguyen QD. Fluocinolone acetonide intravitreal sustained release device - a new addition to the armamentarium of uveitic management. Int J Nanomedicine. 2007;2(1):55-64.
15. Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006;113(6):1020-1027.
16. Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol. 2008;126(9):1191-1201.
17. Jaffe GJ. Reimplantation of a fluocinolone acetonide sustained drug delivery implant for chronic uveitis. Am J Ophthalmol. 2008;145(4): 667-675.
18. Goldstein DA, Godfrey DG, Hall A, et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol. 2007;125(11):1478-1485.
19. Sivaprasad S, McCluskey P, Lightman S. Intravitreal steroids in the management of macular oedema. Acta Ophthalmol Scand. 2006;84(6): 722-733.
20. Edelman JL. Differentiating intraocular glucocorticoids. Ophthalmologica. 2010;2 24 Suppl 1:25-30.
21. Thakur A, Kadam R, Kompella UB. Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. Arch Ophthalmol. 2011;129(7):914-920.
22. Sawyer AJ, Saucier-Sawyer JK, Booth CJ, et al. Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors. Drug Deliv Transl Res. 2011;1(1):34-42.
23. London NJ, Chiang A, Haller JA. The dexamethasone drug delivery system: indications and evidence. Adv Ther. 2011;28(5):351-366.
24. Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52(1):80-86.
25. Chang-Lin JE, Burke JA, Peng Q, et al. Pharmacokinetics of a sustainedrelease dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci. 2011;52(7):4605-4609.
26. Cheng CK, Berger AS, Pearson PA, Ashton P, Jaffe GJ. Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis. Invest Ophthalmol Vis Sci. 1995;36(2):442-453.
27. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007; 125(3):309-317.
28. Williams GA, Haller JA, Kuppermann BD, et al. Dexamethasone posterior- segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol. 2009;147(6):1048-1054.
29. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6): 1134-1146.
30. Lowder C, Belfort R Jr, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129(5):545-553.
31. Ghosn CR, Li Y, Orilla WC, et al. Treatment of experimental anterior and intermediate uveitis by a dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52(6):2917-2923.
32. Kupperman B. Safety and efficacy of dexamethasone intravitreal implant in adjunctive therapy to Lucentis in patients with choroidal neovascularization secondary to age-related macular degeneration. 33rd Annual Macular Society Meeting; February 24, 1010; Tucson, AZ.